Telavancin (Telavancin)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Glycopeptides

Included in the formulation
  • Vibativ
    lyophilizate d / infusion 
    R-PHARM, CJSC     Russia
    • АТХ:

    J.01.X.A.03   Telavancin

    Pharmacodynamics:

    Glycopeptide antibiotic.It breaks the synthesis of the cell wall, blocking the formation of the bacterial membrane by binding to the acyl-D-alanyl-D-alanine mucopeptide, resulting in the formation of spheroplasts.

    It is active against gram-positive microflora: staphylococci, streptococci, micrococci, enterococci, corynebacteria, as well as peptococci and gram-positive anaerobes.

    Pharmacokinetics:

    After intravenous administration, the bioavailability is 90%. The connection with plasma proteins is 90%.

    Metabolism in the liver.

    The half-life is 8 hours. Elimination by the kidneys.
    Indications:

    It is used for the treatment of infectious lesions of the skin and soft tissues, as well as nosocomial, including ventilator-associated pneumonia.

    ICD-10

    X.J10-J18.J18   Pneumonia without clarification of the pathogen

    XII.L00-L08.L08.9   Local infection of skin and subcutaneous tissue, unspecified

    XIII.M70-M79.M79.9   Soft tissue disorder, unspecified

    Contraindications:

    Acute renal failure, simultaneous use with unfractionated heparin sodium, age to 18 years, pregnancy and lactation.

    Carefully:

    Renal insufficiency with creatinine clearance below 50 ml / min and above 10 ml / min, hypersensitivity to vancomycin.

    Pregnancy and lactation:

    Recommendations for FDA - Category C.Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously drip for 60 minutes every 24 hours, 10 mg / kg body weight.

    The highest daily dose: 10 mg / kg body weight.

    The highest single dose: 10 mg / kg body weight.

    Side effects:

    Central and peripheral nervous system: headache, insomnia, confused consciousness, dizziness, unsteadiness of gait, rarely - depression.

    Respiratory system: nasal congestion, bronchospasm, dyspnea.

    Hemopoietic system: leukopenia, neutropenia, agranulocytosis, thrombocytopenia, eosinophilia.

    The cardiovascular system: hyperemia of the face, sensation of hot flashes, thrombophlebitis with intravenous injection.

    Digestive system: decreased appetite, nausea, vomiting, diarrhea, increased levels of alkaline phosphatase and liver transaminases.

    Dermatological reactions: exfoliative dermatitis, toxic skin necrosis, Stevens-Johnson syndrome, abscess at the injection site.

    Sense organs: tinnitus, hearing loss, blurred vision.

    Urinary system: renal failure, urinary tract infections.

    Reproductive system: Candida colpitis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic. It is not removed by hemodialysis.

    Interaction:

    When used simultaneously with aminoglycosides, amphotericin B, furosemide and cyclosporine increases the risk of oto- and nephrotoxic effects.

    Special instructions:

    Monitoring of liver, kidney, hearing and hematopoiesis.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up